arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

IMMUCELL CORP /DE/

ICCC
$10.94 ▼ -0.03 (-0.27%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

IMMUCELL CORP /DE/ faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $99.0M
Dividend Yield
Revenue Growth 28.4%
Op. Margin 19.0%
ROIC 5.2%
FCF / Share $0.38
Trailing P/E 52.1x
Price / Book 3.4x
FCF Yield 3.4%
Debt / Equity 0.30
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.36M
↑ +28.4%
Net Income Profit after all expenses
$1.94M
↑ +34.2%
Operating Margin Operating profit as % of sales
19.0%
↑ +2601.9% 46th
FCF / Share Free cash flow per share
$0.38
↑ +170.8%
Long-Term Debt Long-term obligations
$8.70M
↓ -4.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
37
Returns
39
Financial Health
65
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters